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Abstract
A-to-I RNA editing is a widespread post-transcriptional modification event in vertebrates. It could increase transcriptome
and proteome diversity through recoding the genomic information and cross-linking other regulatory events, such as those
mediated by alternative splicing, RNAi and microRNA (miRNA). Previous studies indicated that RNA editing can occur in a
tissue-specific manner in response to the requirements of the local environment. We set out to systematically detect tissue-
specific A-to-I RNA editing sites in 43 human tissues using bioinformatics approaches based on the Fisher’s exact test and
the Benjamini & Hochberg false discovery rate (FDR) multiple testing correction. Twenty-three sites in total were identified
to be tissue-specific. One of them resulted in an altered amino acid residue which may prevent the phosphorylation of
PARP-10 and affect its activity. Eight and two tissue-specific A-to-I RNA editing sites were predicted to destroy putative
exonic splicing enhancers (ESEs) and exonic splicing silencers (ESSs), respectively. Brain-specific and ovary-specific A-to-I
RNA editing sites were further verified by comparing the cDNA sequences with their corresponding genomic templates in
multiple cell lines from brain, colon, breast, bone marrow, lymph, liver, ovary and kidney tissue. Our findings help to
elucidate the role of A-to-I RNA editing in the regulation of tissue-specific development and function, and the approach
utilized here can be broadened to study other types of tissue-specific substitution editing.
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Introduction
RNA editing is a widespread post-transcriptional modification
mechanism that alters genetic information at the RNA level by
nucleotide insertions, deletions or substitutions, which can
contribute to the diversification of the transcriptome and proteome
[1–2]. C-to-U substitutions and A-to-I substitutions are the two
most common types of RNA editing. C-to-U substitution mostly
exists in higher plant mitochondria and chloroplasts, and it is
defined as the conversion of a single cytidine (C) base to a uridine
(U) through deamination in primary transcripts [2]. A-to-I
substitution, widely found in many vertebrates [3]–[8], is the
modification by members of family of Adenosine Deaminases
Acting on RNA (ADARs) of a single adenosine (A) base in primary
transcripts to yield inosine (I). Since inosine is recognized as
guanosine (G) by the splicing and translational machinery, A-to-I
substitution leads to A-to-G transition in the edited substrate [9].
Nucleotide substitution of RNA editing can change the amino
acid sequence, or create or destroy the translation initiation or
termination codon. Nucleotide insertion or deletion from RNA
editing can result in a translational frameshift that creates new
open reading frames. The consequences of these editing events can
increase the repertoire of available proteins [10–11]. Further-
emore, RNA editing can block the production of mature
microRNA (miRNA) [12]–[14], redirect the miRNA to a new
set of targets [15] and enrich the miRNA regulatory pathways.
Dysregulation of the editing process may also contribute to the
pathogenesis of certain diseases, such as dyschromatosis symme-
trica hereditaria, acute myeloid leukemia and glioblastoma
multiforme [16]–[18].
Previous studies have shown that some RNA editing events are
tissue-specific and play important roles in physiological processes.
More than 100 C-to-U substitutions in grape mitochondria were
shown to be tissue-specific and may contribute to different tissue
requirements[19].A classicexample ofa C-to-Usubstitutionoccurs
in the intestine-specific apolipoprotein in humans, creating a stop
codon and a truncated apoliproprotein-B48 protein, which is less
than half the size of the full-length apolipoprotein-B100 in the liver
[20]. Anther-specific loss of atp6 RNA editing contributes to or
causes cytoplasmic male sterility in Sorghum bicolor [21]. In another
example, ovary/gut-specific U-to-C substitution and nerve cord/
leg-specific A-to-I substitution of BgNav1-1 in cockroachs can
generate tissue-specific functional variants of sodium channels with
distinct gating properties [22]. Therefore, tissue-specific editing is
thought to be required to modulate protein and non-coding RNA
functionality in response to tissue-specific requirements. Systematic
identification of tissue-specific RNA editing can help elucidate the
molecular mechanisms of tissue development and function.
Although tens of thousands of A-to-I RNA editing events have
been found in humans by computational and experimental
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humans. To fully understand of this type of editing event, it is
necessary to perform large-scale discovery and characterization of
tissue-specific A-to-I RNA editing events. The methods based on
expressed sequence tags (ESTs) for large-scale analysis of tissue
specificity have been successfully used to study gene expression [23],
alternative splicing [24–25] and alternative polyadenylation [26].
The vast collection of human ESTs and the associated annotations
alsoprovideanattractiveopportunitytostudytissue-specificityofA-
to-I RNA editing. In this work, we demonstrated the effectiveness of
a computational strategy by using ESTs and mRNA sequence data
to detect tissue-specific A-to-I RNA editing in humans. Twenty-
three A-to-I RNA editing sites were identified to be tissue-specific,
one of which could alter the encoded amino acid and affect the
protein function. Brain-specific and ovary-specific A-to-I RNA
editing sites were further verified by comparing cDNA sequences
with their corresponding genomic templates in several cell lines
from brain, colon, breast, bone marrow, lymph, liver, ovary and
kidney tissue. This strategy may be applied to study other types of
tissue-specific substitution editing in different species.
Results
Computational detection of tissue-specific A-to-I RNA
editing sites
Redundant records of the previously identified A-to-I RNA
editing sites [3–5,8] were removed and the unique sites were
remapped to the assembled human genomic sequence. According
to the alignment information downloaded from the UCSC
genome browser website, all of the expressed sequences overlap-
ping the same RNA editing site were grouped together and
classified into two groups, edited or unedited, based on whether
the nucleotide at the editing position is a guanosine (G) or adenine
(A).
Following strict filters described in the methods section, the final
tissue classification contained 379 cDNA libraries of 43 unique
tissue types. For each tissue, the Fisher’s exact test and the
Benjamini & Hochberg false discovery rate (FDR) multiple testing
correction were applied to detect the tissue-specific A-to-I RNA
editing sites. We finally identified 23 tissue-specific A-to-I RNA
editing sites in 13 different tissues (Table 1). The top four
distributions were tonsil, adipose tissue, pancreas and nerve, which
contained 8, 2, 2 and 2 sites, respectively. Other tissues containing
only one observed tissue-specific event were trachea, thyroid,
salivary gland, pituitary gland, ovary, ear, connective tissue, brain
and blood.
An RNA editing event happens after gene transcription.
Therefore, the expression profile of a gene limits the possibility
of an RNA editing event. To test whether high expression of a
gene in a tissue could increase its RNA editing level in the same
tissue or not, we investigated the tissue-preferred expression of
genes which contain tissue-specific RNA editing sites. By searching
the Tissue-specific Gene Expression and Regulation (TiGER)
database, we found that the CXCL12 gene with a connective-
Table 1. Tissue-specific A-to-I RNA editing sites by computational detection.
Tissue Tissue-specific A-to-I RNA editing site
FDR corrected
P value
Gene related
information
Chromosome Strand Position
adipose tissue chr8 - 117738703 0.000197 EIF3H
chr5 + 150017483 0.007937 SYNPO
tonsil chr6 + 52466294 0.002747 EFHC1
chr6 + 52466305 0.002747
chr6 + 52466312 0.002747
chr6 + 52466320 0.002747
chr6 + 52466321 0.002747
chr6 + 52466350 0.002747
chr6 + 52466400 0.002747
chr6 + 52466401 0.002747
trachea chr3 - 150569793 0.000233 TM4SF1
thyroid chr8 - 11737640 0.001768 CTSB
salivary gland chr15 + 39384948 0.010084
pituitary gland chr4 + 57021844 0.015649 PAICS
pancreas chr15 - 40622466 0.000206 LRRC57
chr15 - 40622469 0.000206
ovary chrX - 128767292 7.79e-008 ZDHHC9
nerve chr8 - 143850023 0.000153 LYNX1
chr14 - 105401091 0.000609
ear chr5 - 81607256 0.000206 RPS23
connective tissue chr10 - 44192920 0.001107 CXCL12
brain chr4 + 57021835 5.43e-006 PAICS
blood chr8 - 145130527 0.001287 PARP10
doi:10.1371/journal.pone.0018129.t001
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other isoforms) was preferentially expressed in soft tissue, heart
and spleen. CXCL12 can activate lymphocytes and take part in
the metastasis of prostate cancer [27]. Connective tissue is the
main component of soft tissue, and high expression of CXCL12 in
soft tissue may increase its RNA editing level in the connective
tissue. However, the vast majority of genes observed here with the
tissue-specific A-to-I RNA editing sites did not show the same
tissue-specificity in their gene expression profiles.
On the other hand, we analyzed the tissue-preferred expression
of all annotated 2,040 genes with 18,616 A-to-I RNA editing sites.
Three hundred and seventy-eight of these genes were expressed in
a tissue-specific manner according to the TiGER database
collection. Except CXCL12 as mentioned above, there was only
one muscle-specific gene, SYNPO (an actin-associated protein),
with an adipose-tissue-specific A-to-I RNA editing site. This
observation indicated that the vast majority of tissue-preferred
genes in this study did not contain putative tissue-specific A-to-I
RNA editing sites.
Therefore, we concluded that the A-to-I RNA editing and the
expression of the corresponding editing substrate did not show the
same tissue preferences in our study. That is, high expression of a
gene does not increase its RNA editing level, and the tissue-specific
editing can exist in transcripts that are widely expressed.
Experimental verification of brain-specific and ovary-
specific RNA editing sites
To experimentally validate the predicted brain-specific and
ovary-specific editing sites, two human tissue samples (brain) and
ten human cell lines (from brain, ovary, colon, breast, bone, bone
marrow, lymph, liver, and kidney) were used. We sequenced
matching DNA and RNA samples retrieved from the same
specimen. As shown in Figure 1a and 1c, the edited substrates
were amplified successfully in all tissue samples and cell lines. The
absence of visible bands in the no-RT controls confirmed that
there was no DNA contamination in RNA used to generate the
cDNA. The PCR products were sequenced as a population
without cloning. When the PCR products were directly sequenced,
editing was determined by the presence of an unambiguous trace
of guanosine in positions for which the genomic DNA clearly
indicated the presence of an adenosine. We verified the predicted
brain-specific editing events in both the brain tissue samples and
the human glioma cell line SF126 (Figure 1b) and the predicted
ovary-specific editing events in two human ovarian cancer cell
lines (SKOV3 and OVCAR3, Figure 1d). The editing level was
represented as a percentage estimated from the ratio of the ‘G’
peak over the sum of the ‘G’ and ‘A’ peaks in the sequencing
chromatogram. The estimated editing level of brain-specific RNA
editing was 17.7% (151/855) in the Brain1 tissue sample, 22.6%
(240/1061) in the Brain2 tissue sample and 10.1% (85/842) in the
glioma cell line SF126. No corresponding editing events were
observed in the other 6 cell lines from colon, breast, bone marrow,
lymph, liver and kidney (Figure 1b). The positive experimental
results obtained only in the brain tissue and cell line indicated that
the A-to-I RNA editing event that occurred at site chr4_+_
57021835 was brain-specific. The estimated editing level of ovary-
specific RNA editing was 16.8% (171/1015) in the human ovarian
cancer cell line OVCAR3 and 7.9% (70/888) in the human
ovarian cancer cell line SKOV3. No corresponding editing events
were observed in the other 8 cell lines from brain, colon, breast,
bone, bone marrow, lymph, liver, and kidney (Figure 1d). The
positive experimental results obtained only in the two human
Figure 1. Experimental validation of the predicted brain-specific and ovary-specific RNA editing sites. (A) The up/downstream region of
the brain-specific RNA editing site was amplified successfully from cDNAs and gDNA of two adjacent non-cancerous brain tissues, as well as the
HepG2, K562, MDA-MB-231, 293T, Raji, SW480 and SF126 cell lines. (B) Sequencing results of paired genomic DNA (control) and cDNA from the same
human brain specimens and seven human cell lines. A mixed peak of A and G in the cDNA sample but not in the genomic counterpart indicates the
presence of RNA editing in both adjacent non-cancerous brain tissues and the human glioma cell line SF126. (C) The up/downstream region of the
ovary-specific RNA editing site was amplified successfully from cDNAs and gDNA of the OVCAR3, SKOV3, SF126, HepG2, Raji, 293T, SW480, U2OS,
K562 and MDA-MB-231 cell lines. (D) Sequencing results of paired genomic DNA (control) and cDNA from the same ten human cell lines. A mixed
peak of A and G in the cDNA sample but not in the genomic counterpart indicates the presence of RNA editing in the two human ovarian cancer cell
lines SKOV3 and OVCAR3.
doi:10.1371/journal.pone.0018129.g001
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event which occurred at site chrX_2_128767292 was ovary-
specific.
Tissue-specific RNA editing sites in protein coding
regions
Some A-to-I RNA editing sites are located in protein-coding
regions, whereas the majority is found in non-coding regions. An
editing site within the protein-coding region of an mRNA can
result in a sequence change that may lead to an amino acid
alteration in the protein. By analysis using EditFunc, one blood
tissue-specific RNA editing site was found to alter an amino acid
residue. The editing site mapped to chr8_2_145130527 changes
the serine residue at position 507 of the PARP-10 protein
(Genbank accession: NP_116178) to a glycine residue, which was
predicted as a putative phosphorylation site by the EditFunc web
server with the use of the NetPhos software [28]. Phosphorylation
of a serine, a threonine or a tyrosine residue is one of the most
common mechanisms of regulating protein function. Therefore,
this blood-specific editing event may prevent the phosphorylation
of PARP-10 and alter its activity.
PARP-10 belongs to the family of Poly (ADP-ribose) polymer-
ases, which regulates gene transcription by altering chromatin
organization by adding ADP-ribose to histones. PARP-10 was
reported to interact with the Myc protein and inhibit cell
proliferation [29]. From its tissue expression pattern, PARP-10 is
preferentially expressed in hematopoietic tissues, although it can
be detected in 16 different tissue types [29]. The blood-specific
editing of PARP-10 showed a similar preference in its expression
profile, implying that the blood-specific editing may be involved in
the control of cell proliferation in hematopoietic tissues.
Tissue-specific RNA editing sites in exonic splicing
enhancers (ESEs) and exonic splicing silencers (ESSs)
In recent years, some evidences have accumulated showing that
splicing and editing can influence each other [30]–[33]. To
investigate whether the tissue-specific A-to-I editing may disrupt
the functional elements of ESE and ESS, we analyzed the edited
and unedited exon sequences with the EditFunc web server using
the programs ESEfinder [34–35] and FAS-ESS [36]. Eight tissue-
specific A-to-I editing sites were predicted to alter the SF2/ASF,
SC35 and SRp40 ESE motifs (Table S1), and two tissue-specific A-
to-I RNA editing sites were predicted to change four ESS hexamers
(GGGAGG, TAGGTA, TTAGGT and CTTAGG, Table S2). It
has been shown that the mutation of an ESE or ESS sequence can
inactivate its function and affect pre-mRNA splicing [37–38].
Therefore, these tissue-specific A-to-IRNA editingsites may disrupt
ESEs or ESSs and lead to changes in transcript splicing patterns.
Discussion
RNA editing is an important post-transcriptional regulation that
can increase protein diversity and enrich the regulation of non-
coding RNA. Although a few studies have indicated that RNA
editing is an indispensable modulation in response to the
requirements of specific cell types, it has been a challenge to gain
an overview of the global landscape of tissue-specific editing. In
this study, we successfully detected human tissue-specific A-to-I
editing sites by statistically analyzing EST/mRNA sequences. The
overwhelming majority of the known RNA editing sites used here
was found in the non-coding sequences, and most of the predicted
editing sites were located in the non-coding regions as well. By
gaining a deeper understanding of the non-coding sequences, we
should begin to know more about the functions of the tissue-
specific RNA editing.
Interestingly, most of the genes containing the tissue-specific A-
to-I RNA editing did not exhibit tissue-specific expression. On the
contrary, many tissue-specific genes were not discovered to have
the predicted tissue-specific A-to-I RNA editing sites, although we
could not exclude the possibility that they may have other
unknown tissue-specific RNA editing sites. This implies that the
tissue-specific editing event is a modulatory mechanism required
for tissue-specific development but that its role is independent of
the regulation of tissue-specific gene expression. The members of
the family of ADARs are the only enzymes that are known to
regulate A-to-I RNA editing levels. However, it seems that the
regulation by ADARs cannot completely explain how tissue-
specific editing occurs. Recent studies indicated that editing levels
can increase or decrease with a constant (or not significantly
changed) protein expression of ADARs [39–40], consistent with
the opinion of Jacobs and colleagues that the differences in editing
patterns may not be mediated solely by ADAR expression levels
[41]. Take together, these observations indicate that there may be
factors in addition to the ADARs that are involved in the tissue-
specific A-to-I RNA editing process.
RNA-seq data can also be used to detect tissue-specific editing if
the read sequences are treated as EST/mRNA sequences.
However, the high expense of whole genome and transcriptome
sequencing currently restricts its application for RNA editing
analysis, and there are only three published works that have utilized
high-throughput sequencing to detect RNA editing at present [8]
[19] [39]. Furthermore, the application of whole genome and
transcriptome sequencing for detection of the human tissue-specific
A-to-I RNA editingwould be evenmore costly. For each individual,
whole genome sequencing should be performed once or twice
(replicate), and whole transcriptome sequencing should be per-
formed in each tissue. For studies involving different donors, whole
genome and transcriptome sequencing would be required for each
donor and their tissues, significantly adding to the overall cost and
labor requirements. However, with the development of lower cost
nextgenerationsequencingtechnology,significantly more data may
be accumulated, and it is expected that more reliable and novel
observations will be realized by using this approach.
Finally, we have to note that there are probably many more
tissue-specific editing sites than those identified in this work for the
following reasons. (i) The coverage of expressed sequences in the
same editing sites in all tissues are not equivalent. Therefore, many
editing sites may be detected in a only few tissues but not in others
where there are just too few or no expressed sequences. (ii) The
Fisher’s exact test with the Benjamini & Hochberg correction is
usually considered strict and may cause us to miss detection of
some true tissue-specific editing sites. (iii) Finally, many A-to-I
RNA editing sites have been uncovered to date, and the 23 tissue-
specific A-to-I RNA editing sites predicted here still represents a
small portion of the actual tissue-specific RNA editing repertoire.
Nevertheless, this is the first study to explore tissue-specific A-to-I
RNA editing in humans, and the information gained here may
facilitate the understanding of regulation by RNA editing related
to the unique functions of tissues.
Materials and Methods
Data sources
Five sources of data were required for our analysis, including
known A-to-I RNA editing sites, the human reference genomic
sequences, the human mRNA/EST sequences, the alignments
between the human mRNA/EST and reference genome sequenc-
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32,316 non-redundant A-to-I RNA editing sites identified by
different methods were collected from four published works [3]–
[5] [8]. The other four resources, such as the human reference
genomic sequences (hg18), the mRNA/EST sequences, the
‘gbCdnaInfo.txt’ flat file (alignment between the human
mRNAs/ESTs and genome sequences), and the ‘tissue.txt’ flat
file (human mRNA/EST library information) were all download-
ed from the UCSC genome browser website [42]. First, all of the
known editing sites were remapped to the human genome
sequences (hg18). Subsequently, the expressed sequences of
mRNAs/ESTs overlapping the same RNA editing site were
grouped together based on the alignment information. Every
grouped mRNA or EST sequence was classified as edited or
unedited according to whether the nucleotide at the position of the
known editing is a guanosine (G) or adenine (A).
Tissue classification
Four hundred and ninety cDNA libraries with tissue annota-
tions were downloaded from the UCSC website. A total of 111
cDNA libraries were excluded from the original set because these
libraries lacked clear tissue source information or were from mixed
tissue samples. Furthermore, libraries recorded as having the same
tissue source (e.g. ‘brain’) were combined into a single category,
including both normal and cancerous samples from the same
tissue. Finally, we filtered and grouped 379 cDNA libraries into 43
unique tissue types (Table 2).
Determination of tissue specificity
As a measure of tissue-specificity, Fisher’s exact test was applied
to assess the significance of different RNA editing levels in all
tissues, and the Benjamini-Hochberg method was used to estimate
the total FDR in each tissue for correction of multiple testing.
For each RNA editing site i, NGT
i and NAT
i represent the total
numbers of ESTs/mRNAs in tissue T observed in edited form or
unedited form, respectively. Similarly, NGT
i and NAT
i are the total
numbers of ESTs/mRNAs in the pool of all other tissues observed
in editedform or unedited form, respectively.The Fisher’s exact test
was used to compute thePivalue from any 2 by 2 table.
The following simple procedure to control the FDR at level a was
proposed by Benjamini and Hochberg [43]. For m tests in tissue T,
the P values were ranked in ascending order P1ƒP2ƒƒPm
and the null hypothesis corresponding to Pi was denoted byHi. The
k variable represented the largest i for which Piƒ a
mi and all null
hypothesesH1 Hk were rejected. In other words, each P value
(starting with the highest) was checked for this requirement; at the
first P value that met the requirement, its corresponding null
hypothesis and all those having smaller Pvalues were rejected. The
desired confidence level was 0.95 (a=0.05).
Expression profiles of tissue-specific genes
To explore whether genes containing the A-to-I RNA editing
sites were expressed in a tissue specific manner or not, we searched
their expression profiles from the TiGER database [44]. This
database contains a collection of 7,261 tissue-specific genes from
30 tissues based on the expression enrichment (EE) values and
statistical significance.
Clinical samples and cell lines
Two brain adjacent non-cancerous tissue samples and ten cell
lines were used in this study for experimental validation. The brain
tissue samples were obtained from the 307 Hospital of PLA with
the written informed consent of patients and with approval for
experiments from the ethics committees of the hospital and the
Beijing Institute of Biotechnology. The human glioma cell line
SF126 was purchased from the Cancer Institute and Hospital,
Chinese Academy of Medical Sciences (CAMS). The two human
Table 2. Distribution of mRNA/EST sequences and cDNA
libraries identified with A-to-I editing sites among 43 tissue
types.
Tissue No. of libraries No. of mRNAs/ESTs
adipose tissue 5 68
adrenal gland 5 120
ascites 1 76
bladder 2 22
blood 10 139
bone 12 385
bone marrow 10 101
brain 52 3090
cervix 6 127
connective tissue 6 161
ear 1 17
esophagus 3 23
eye 22 583
heart 2 25
intestine 20 366
kidney 13 336
larynx 3 4
liver 10 473
lung 16 438
lymph 19 429
lymph node 2 187
mammary gland 11 271
mouth 7 148
muscle 6 233
nerve 23 651
ovary 8 169
pancreas 10 707
parathyroid 1 62
pharynx 1 41
pituitary gland 3 47
placenta 9 566
prostate 11 265
salivary gland 3 62
skin 23 488
spleen 2 271
stomach 4 78
testis 6 386
thymus 1 520
thyroid 4 79
tonsil 4 292
trachea 1 200
uterus 18 506
vascular 3 13
doi:10.1371/journal.pone.0018129.t002
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by Peng Peng (Peking Union Medical College Hospital, Beijing,
China). The human colon cancer cell line SW480, the human
estrogen receptor (ER)-negative breast cancer cell line MDA-MB-
231 and the human osteosarcoma cell line U2OS were supplied by
Xuemin Zhang (National Center of Biomedical Analysis, Beijing,
China). The human chronic myeloid leukemia cell line K562 and
the human Burkitt’s lymphoma cell line Raji were gifts from
Qingfeng Du (Nanfang Hospital, Southern Medical University,
Guangzhou, China). The human renal epithelial cell line 293T
and the human hepatoma cell line HepG2 were supplied by Yan
Lin (Beijing Institute of Biotechnology, Beijing, China).
Cell culture
K562, SW480, SKOV3 and Raji cell lines were cultured in
RPMI 1640 media (Gibco) supplemented with 10% fetal bovine
serum (FBS, Gibco), 100 U/ml penicillin and 0.1 mg/ml
streptomycin (Hyclone). HepG2, MDA-MB-231, OVCAR3,
U2OS and 293T cell lines were grown in Dulbecco’s Modified
Eagle Medium (DMEM) (Gibco) with 10% FBS, 100 U/ml
penicillin and 0.1 mg/ml streptomycin. SF126 was maintained in
Minimum Essential Medium (MEM) (Gibco) with 10% FBS,
100 U/ml penicillin and 0.1 mg/ml streptomycin. All cells were
cultured at 37uC in a 5% CO2 incubator with humidified air.
RNA extraction and RT-PCR
For experimental validation of brain and an ovary tissue-specific
RNA editing sites, total RNA and gDNA of two brain tissue
samples isolated from the same specimen and ten cell lines were
processed using standard protocols for reverse transcription and
PCR. To remove genomic DNA contamination, RNA samples
were treated with DNase I (Takara, Otsu, Shiga, Japan). First-
strand cDNA was synthesized from the total RNA with the
Transcriptor High fidelity cDNA Synthesis Kit (Roche) using
random primers. Using the cDNA and gDNA as templates, PCR
was performed according to standard procedures with 30 pM of
each primer and 2.5 U rTaq DNA polymerase (Takara, Otsu,
Shiga, Japan) to amplify the edited transcripts and the genomic
DNA. The cycling conditions for amplification were as follows:
initial denaturation at 95uC for 5 min, then 30 cycles at 95uC for
30 s, 59uC for 30 s, and 72uC for 30 s, followed by a final
extension at 72uC for 10 min. Control experiments were
conducted without the reverse transcriptase enzyme added (no
RT control) to verify that the amplified products were from the
reverse transcribed mRNA and not from contaminating genomic
DNA. The products were resolved by electrophoresis on a 1% w/v
agarose gel in TAE buffer (40 mmol/L Tris-acetate, 2 mmol/L
Na2EDTA, 2H2O) and stained with ethidium bromide. Finally,
DNA bands were quantified using a Gel Imaging Analysis System
BINTA 2020D and the GelPro32 software (Beijing BINTA
Instrument Technology Co., Ltd., China). The primers were
synthesized by Beijing AuGCT Biotechnology Co., Ltd, and
sequencing of PCR products was performed by Beijing Tianyi
Huiyuan Life Science & Technology, Inc. The following primers
were used to detect the genomic DNA and mRNA:
BR-L: 59-TggTTCTTgggTTCTCCCgAAgCCT-39,
BR-R: 59-AggTACCAATgTgTggCAgTCCA-39,
OV-L: 59- AAATCCTCCCAAgCTgCTgCACg-39,
OV-R: 59- AgTgCTgggCTTTCCCTCACTCA-39.
Predicting the functional effects of tissue-specific RNA
editing sites
EditFunc (http://www.compbio.net.cn/editfunc), a web server
for predicting potential effects of RNA substitution editing, was
used to predict the functional effects of the tissue-specific RNA
editing sites. EditFunc can predict the effects of the RNA editing
sites at the transcriptional level, including changes in canonical
splice site sequences, exonic splicing enhancers, exonic splicing
silencers, Piwi-interacting RNAs (piRNAs) and miRNAs com-
pared with their targets. It can also predict the effects of RNA
editing sites at the translational level, including alterations in the
initiation codon, termination codon, amino acid residues,
physicochemical properties, glycosylatioin sites, phosphorylation
sites, propeptide cleavage sites and signal peptide domains.
According to the annotated piRNA [45], miRNA [46] and the
corresponding target datasets [47], five EditFunc prediction
options for piRNA, miRNA target, precursor miRNA, mature
miRNA and miRNA seed allow the user to detect whether the
queried editing site is located at non-coding RNAs and their
functional regions or not. The splice sites, translational initiation
and termination codons were detected in the genome by the
GeneID program [48], and the results were used to identify
whether the RNA editing site may damage the normal mRNA
splicing or protein translation processes.
The putative ESSs were scanned in all exon sequences of
human genes by using the FAS-hex-3 set [36]. RNA editing sites
located at these ESSs were cataloged as potential sites that could
disturb the silencer activity. EditFunc was also used to scan exon
sequences based on previously published nucleotide-frequency
matrices [35] to identify putative ESEs responsive to the human
serine/arginine-rich proteins (SR proteins) SF2/ASF, SC35,
SRp40 and SRp5. ESEs with scores over the threshold [35] were
regarded as the functional elements in this study. If the RNA
editing site reduced the score of the ESE to below threshold value,
it was annotated as a potential site that could disrupt activity at this
ESE.
Six EditFunc prediction options for propeptide cleavage site,
signal peptide, N-linked glycosylatioin, O-linked glycosylatioin, C-
linked glycosylatioin and Phosphorylation were used to first
execute external programs Prop [49], Signalp [50], netNglyc
(http://www.cbs.dtu.dk/services/NetNGlyc/), netOglyc [51],
netCglyc[52] and Netphos [28], and then to map the RNA
editing sites to these protein functional sites or domains and to
assess their potential effects on normal protein processing or post-
translational modification.
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